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Background:  Despite pharmacological advances, the non-invasive therapeutic options for patients with late-stage HF remain limited, 
in particular for those refractory to management and with poor renal function. The Aortix™ system is a novel percutaneous intra-aortic 
assist device, which may circumvent the limitation(s) of invasive cardio-renal support. Here, the acute effects of Aortix support on load-
independent cardio-renal function and ventriculo-arterial coupling were evaluated in sheep with ischemic HF.
methods:  Sheep (n = 4) were instrumented for the determination of systemic/left-ventricular (LV) hemodynamics, cardiac-output, 
load-independent inotropy/lusitropy and ventriculo-arterial coupling (via pressure-volume relationships), as well as for the assessment 
of myocardial O2 extraction (O2ex) and renal function. Sheep had HF induced via serial (weekly) coronary embolizations, resulting in 
depressed LV function (EF: 34 ± 7%) and elevated filling pressures (EDP: 20 ± 1mmHg). In this setting, the Aortix device was deployed 
(using a catheter-based approach) into the descending aorta. LV mechano-energetics and renal responses were evaluated before/during/
after 30min bouts of continuous support.
results:  Aortix-support decreased the arterial elastance (Ea: -26 ± 4%, 2.1 ± 0.1 to 1.6 ± 0.1* mmHg/mL) with no chronotropy (105 ± 11 
to 103 ± 9 bpm). Ejection fraction (EF: +39 ± 12%, 34 ± 1 to 48 ± 5*%) and cardiac output (CO: 4.0 ± 0.5 to 4.7 ± 0.8 L/min) increased with 
support, while myocardial O2ex decreased (17 ± 3 to 12 ± 4*%); LV pressure-volume area also decreased with support (6.1 ± 0.9 to 3.7 ± 
0.5* mmHg*L). Concomitantly, both urine output (+102 ± 23%*) and renal flow (+15 ± 1%*) increased with support. Steeper ESPVR and 
PRSW slopes (e.g., 46 ± 5 to 55 ± 6* mmHg) were observed post-treatment, suggesting positive inotropy and improved ventriculo-arterial 
coupling (Ea/Ees: 1.3 ± 0.0 to 0.7 ± 0.0*). *: P < 0.05.
conclusion:  The Aortix, a novel catheter based intra-vascular assist device, acutely decreased myocardial loading and energetic demand, 
while improving LV function, ventriculo-arterial coupling, and providing renal support in the setting of ischemic heart failure. 
